Page last updated: 2024-09-04

tariquidar and azides

tariquidar has been researched along with azides in 2 studies

Compound Research Comparison

Studies
(tariquidar)
Trials
(tariquidar)
Recent Studies (post-2010)
(tariquidar)
Studies
(azides)
Trials
(azides)
Recent Studies (post-2010) (azides)
2101613811,337183,204

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bootle, D; Charlton, P; Dangerfield, W; Liddle, C; Mistry, P; Okiji, S; Plumb, JA; Stewart, AJ; Templeton, D1
Ambudkar, SV; Barnett, D; Bates, SE; Finley, EM; Fojo, T; Oldham, RK; Robey, RW; Shukla, S1

Trials

1 trial(s) available for tariquidar and azides

ArticleYear
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
    Biochemical pharmacology, 2008, Mar-15, Volume: 75, Issue:6

    Topics: Adenosine Triphosphatases; Alkaloids; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Biological Factors; Biological Transport; Cell Line; Cell Line, Tumor; Cyclosporins; Depsipeptides; Fluorescent Dyes; Fluorouracil; Humans; Insecta; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Prazosin; Quinolines; Rhodamine 123; Verapamil; Vinblastine

2008

Other Studies

1 other study(ies) available for tariquidar and azides

ArticleYear
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
    Cancer research, 2001, Jan-15, Volume: 61, Issue:2

    Topics: Acridines; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Binding, Competitive; Cell Division; Cyclosporins; Daunorubicin; Dihydropyridines; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Isoquinolines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Quinolines; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Tritium; Xenograft Model Antitumor Assays

2001